<DOC>
	<DOC>NCT02070380</DOC>
	<brief_summary>This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.</brief_summary>
	<brief_title>Crossover Comparison of MultiHance and Dotarem</brief_title>
	<detailed_description>This crossover study aims at a comparison between 0.1 mmol/kg MultiHance and 0.1 mmol/kg Dotarem, between 0.05 MultiHance and 0.1 mmol/kg Dotarem in terms of diagnostic preference at CE-MRI in brain tumor patients to show superiority of MultiHance.</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<criteria>Are at least 18 years of age or older Are able to give written informed consent and are willing to comply with the protocol requirements Are scheduled to undergo MRI Are willing to undergo two MRI procedures within 14 days Have confirmed or are highly suspected to have brain tumor(s) (primary or secondary), as determined by: Clinical/neurological symptomatology; Diagnostic testing, such as CT or previous MRI examinations; or Have had recent brain surgery and are to be evaluated for recurrence Are pregnant or lactating females. Exclude the possibility of pregnancy: By testing on site at the institution within 24 hours prior to the start of each investigational product administration; or By history (i.e., tubal ligation or hysterectomy); or Post menopausal with a minimum of 1 year without menses Have any known allergy to one or more of the ingredients in the investigational products, or have a history of hypersensitivity to any metals Have congestive heart failure (class IV according to the classification of the New York Heart Association) Have suffered a stroke within a year Have received or are scheduled to receive any other contrast medium in the 24 hours preceding through the 24 hours following Exam 1, and in the 24 hours preceding through the 24 hours following Exam 2 Have received or are scheduled to receive an investigational compound and/or medical device within 30 days before admission into the present study, through the 24 hours postadministration of the second investigational product Have moderatetosevere renal impairment, defined as Glomerular Filtration Rate (GFR)/estimated GFR &lt; 45 mL/min Have been previously entered into this study Have received or are scheduled for one of the following: Surgical or chemotherapeutic treatment within three weeks prior to the first examination or between the two examinations Initiation of steroid therapy between the two examinations Radiosurgery between the two examinations Have any contraindications to MRI such as a pacemaker, magnetic material (i.e., surgical clips) or any other conditions that would preclude proximity to a strong magnetic field Are suffering from severe claustrophobia Have any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or postdose followup examinations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>confirmed brain disease</keyword>
	<keyword>highly suspected brain disease</keyword>
</DOC>